Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management
Biotronik Nro, Inc. · Decision date Apr 24, 2026
What did the FDA decide?
FDA records P210037/S015 as a supplement to PMA P210037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 24, 2026.
FDA approval order statement
to remove two redundant incoming inspections (Bend Test and X-Ray Test) conducted on the Resilience percutaneous leads
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Apr 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210037/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik Nro, Inc.
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Apr 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Biotronik Nro, Inc.
- Product code
- LGW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P210037/S013 · Related supplement
Prospera SCS System; Resilience Percutaneous Lead; Embrace One; TrueLock
P210037/S015 received
Application receipt date recorded by FDA.
P210037/S015 · FDA decision
30-Day Notice
P210037/S012 · Related supplement
Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management
P210037/S017 · Related supplement
Prospera Spinal Cord Stimulation (SCS) System; Resilience Percutaneous Lead; Embrace One; TrueLock
Timeline entries are records held by MedtechLedger for P210037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik Nro, Inc. | PMA supplement | Oct 23, 2025 | FDA | |
| Biotronik Nro, Inc. | PMA supplement | May 14, 2026 | FDA | |
| Biotronik Nro, Inc. | PMA supplement | Jun 5, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik Nro, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P210037/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




